The RECOVER I: A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support

Abstract

The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.

Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era

“…3 Instead, short-term ventricular assist devices (VADs), which generally consist of internal cannulae and an external pump, have been developed for this application and have become a widely accepted treatment option in RCS. [4][5][6][7][8] In addition, there has been a resurgence of interest in veno-arterial extracorporeal membrane oxygenation (VA ECMO), as this approach has become safer and more reliable. [9][10][11][12][13] The bridge-to-transplant or destination therapy devices, as the second-stage treatment, require more durability and reliability, as well as feasibility of outpatient management.…”

Impella to Unload the Left Ventricle During Peripheral Extracorporeal Membrane Oxygenation

“…Impella 2.5 (Abiomed, Danvers, MA) is a catheter-mounted microaxial rotary pump capable of displacing 2.5 L of blood per minute, draining blood from the LV, and delivering it to the aortic root using the venturi effect. [12][13][14][15] It has been used to augment the cardiac output and to unload the LV in the setting of cardiogenic and postcardiotomy shock. [12][13][14][15] Use of the Impella in the adult population as a short-term bridge to long-term mechanical support has also been described.…”

“…[12][13][14][15] It has been used to augment the cardiac output and to unload the LV in the setting of cardiogenic and postcardiotomy shock. [12][13][14][15] Use of the Impella in the adult population as a short-term bridge to long-term mechanical support has also been described. 15,16 We present our experience with the Impella 2.5 (Abiomed) as an adjunct for aggressive LV unloading during femoral VA ECMO support before implantation of a HeartMate II (Pleasanton, CA) long-term VAD.…”

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

“…LVADs enhance total cardiac output by adding to that of the damaged native heart, potentially allowing myocardial recovery, particularly in patients with cardiogenic shock [30][31][32][33][34].…”